Building a clinical cohort for Alzheimer's disease research
Duke/UNC Alzheimer's Disease Center Clinical Cohort
This study is trying to create a group of people with different memory and thinking abilities, aged 25 to 80, to help researchers learn more about Alzheimer's disease and related conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 25 Years to 80 Years |
| Sex | All |
| Sponsor | Duke University Academic / other |
| Locations | 1 site (Durham, North Carolina) |
| Trial ID | NCT06703541 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a clinical cohort for the Duke/UNC Alzheimer's Disease Research Center, enrolling individuals aged 25 to 80 with varying cognitive statuses, including normal cognition, mild cognitive impairment, and dementia. Participants will undergo comprehensive assessments, including medical history, physical exams, neuropsychological testing, and various biological sample collections. The cohort will be followed annually for ongoing evaluation and data collection to better understand the impact of age, sex, and genetics on neurodegenerative disorders. The data collected will be de-identified and used to advance research in Alzheimer's disease and related dementias.
Who should consider this trial
Good fit: Ideal candidates include adults aged 25 to 80 with normal cognition, mild cognitive impairment, or a dementia diagnosis, who are willing to participate in extensive assessments.
Not a fit: Patients with significant cognitive impairment or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Alzheimer's disease and improve early detection and intervention strategies for patients.
How similar studies have performed: Other studies have successfully established similar cohorts, indicating that this approach is both tested and valuable for advancing Alzheimer's research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Each subject must be ≥ 25 to ≤ 80 years of age. * Each subject must be able to read at a 6th grade level, as determined by the investigator, and must have a history of academic achievement and/or employment sufficient to exclude intellectual disability. * Each subject (or legal representative) must sign the informed consent form after the scope and nature of the investigation have been explained to them, and before screening assessments. Some consent may be obtained via phone script and REDCap eConsent. * Each participant must be willing to have an MRI and a lumbar puncture, or alternately (to the lumbar puncture) a series of PET scans. * Each participant ages 45 to 80 must have a study partner who agrees to participate in the study and who is able to read at a 6th grade level, as determined by the investigator, and must have a history of academic achievement and/or employment sufficient to exclude intellectual disability. Exclusion Criteria: * Evidence of a clinically relevant or unstable neurological disorder including history of multiple head injuries, stroke or other CNS conditions (MS, Parkinson's disease, etc.) * Evidence of a clinically relevant or unstable psychiatric disorder. * History of alcoholism or drug dependency/abuse within the last 2 years before enrollment. * GAD-7 score \>9 and/or PHQ-8 score \>9 * An ongoing uncontrolled, clinically significant medical condition such that, in the judgment of the investigator, a subject's participation in the trial would pose a significant medical risk to the subject. * Contraindication or intolerance to 3T MRI investigations, including implanted devices * History of malignancy of any organ system, treated or untreated, within the past 60 months, regardless of whether there is evidence of local recurrence or metastases. However localized nonmalignant tumors not requiring systemic chemo- or radiotherapy, localized basal or squamous cell carcinoma of the skin, or in-situ cervical cancer are permitted.
Where this trial is running
Durham, North Carolina
- Duke University — Durham, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Heather E Whitson, MD, MHS — Duke University
- Study coordinator: Rachel Dewees, MSW
- Email: adrc@duke.edu
- Phone: 919-660-2340
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.